Organon & Co

Stable6 articles3 sourcesDernière mise à jour: 28/04/2026

Sujets associésacquisition pharmaceuticals merger women's health biosimilars organon india united states

Derniers articles

Business·28/04/2026Résumé IA

Sun Pharma Acquires Organon & Co for $11.8 Billion in Largest-Ever Overseas Pharma Deal by Indian Company

Sun Pharma, India's largest pharma company, has acquired US-listed Organon & Co for $11.8 billion (Rs 98,000 crore) in an all-cash transaction — the biggest-ever overseas pharma deal by an Indian company. Sun Pharma will pay $14 per share, a 24% premium to Organon's closing price. The acquisition adds over 140 high-growth markets including China, and portfolio of women's health, biosimilars, and legacy brands. Once completed, it will double Sun Pharma's revenue to $12.4 billion and EBITDA to $3.7 billion, ranking it among top 25 global pharmaceutical companies.

Times of India

1 min de lecture

Sun Pharma Acquires Organon & Co for $11.75 Billion

En développement

Business·27/04/2026Résumé IA

Sun Pharma Acquires Organon & Co for $11.75 Billion

Sun Pharma has acquired Organon & Co for $11.75 billion, a deal designed to enhance its global commercial reach and diversify its portfolio into women's health and biosimilars, despite concerns regarding increased debt and integration challenges.

Economic Times

2 min de lecture

Sun Pharma to Acquire Organon for $11.75 Billion in Landmark Deal

En développement

Business·27/04/2026Résumé IA

Sun Pharma to Acquire Organon for $11.75 Billion in Landmark Deal

Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co for $11.75 billion in an all-cash deal. The acquisition values Organon at $14 per share and will help lift the Indian generics major into the top 25 global pharmaceutical companies with combined revenue of $12.4 billion. Organon, spun off from Merck in 2021, specializes in women's health and biosimilars with over 70 products sold across 140 countries. The deal will increase Sun Pharma's innovative medicine segment contribution from 20% to 27% of total sales.

Sun Pharma shares jump 5% as India's largest drugmaker to buy U.S. firm Organon in $11.75 billion deal

To fuel its global ambitions, Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal that values the U.S. company at $11.75 billion.

CNBC

Sun Pharma to Acquire Organon for $11.75 Billion in Landmark Pharma Deal

Urgent

Business·27/04/2026Résumé IA

Sun Pharma to Acquire Organon for $11.75 Billion in Landmark Pharma Deal

Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co for $11.75 billion in an all-cash deal. The Indian drugmaker will pay $14 per share for all outstanding Organon shares, which was spun off from Merck in 2021. The acquisition will create a pharmaceutical giant with $12.4 billion in revenue, lifting Sun Pharma into the top 25 global pharmaceutical companies. Organon specializes in women's health and biosimilars with over 70 products sold across 140 countries.

Indian drugmaker Sun Pharma to buy U.S. firm Organon in $11.75 billion deal

To fuel its global ambitions, Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal that values the U.S. company at $11.75 billion.

CNBC